Benchmarking Multimodal AI Risk Estimates in Localized Prostate Cancer

EP. 1: Closing Risk Stratification Gaps in Localized Prostate Cancer With AI

Published: October 2nd 2026 | Updated: October 2nd 2026

Daniel Spratt, MD, outlines the limitations of PSA-, T stage-, and Gleason-based risk stratification and explains how AI-derived, continuous risk estimates could address them.

Trending on Urology Times

Benchmarking Multimodal AI Risk Estimates in Localized Prostate Cancer

EP. 1: Closing Risk Stratification Gaps in Localized Prostate Cancer With AI

Trending on Urology Times

John Sfakianos, MD, on integrating ctDNA into bladder cancer trials

FDA updates in urology: September 2026

AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI

Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR

SBRT, prostatectomy show comparable long-term disease control in PACE-A trial